Sigilon Therapeutics, Inc. – Trademark Portfolio
Entity Type: 03
Sigilon Therapeutics, Inc. holds 8 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 1 (Chemicals) — 8 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 3 Nice Classification classes. Currently, 6 trademarks are registered. Notable registered marks include SLTX, SIGILON, AFIBROMER, AFIBROTEK, and SIGILON THERAPEUTICS. The owner is based in Cambridge, MA.
100 Binney Street, Suite 600
Cambridge, MA 02142
Showing of trademarks Trademarks
Trademark Classifications
Sigilon Therapeutics, Inc.'s trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does Sigilon Therapeutics, Inc. have?
Sigilon Therapeutics, Inc. has 8 U.S. trademarks filed with the USPTO. Of these, 6 registered, 2 abandoned.
What trademark classes does Sigilon Therapeutics, Inc. file in?
Sigilon Therapeutics, Inc. files trademarks across 3 Nice Classification classes. The most active classes are Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus). Class 1 covers chemical products for industry, science, photography, agriculture, horticulture and forestry.
What are Sigilon Therapeutics, Inc.'s most well-known trademarks?
Sigilon Therapeutics, Inc.'s registered trademark portfolio includes well-known marks such as SLTX, SIGILON, AFIBROMER, AFIBROTEK, and SIGILON THERAPEUTICS. These are among 6 currently registered trademarks in the portfolio.
What is Sigilon Therapeutics, Inc.'s trademark registration success rate?
Sigilon Therapeutics, Inc. has a 75% trademark registration rate, with 6 out of 8 resolved applications resulting in successful registration. Currently, 0 applications are pending review.